Welcome to our dedicated page for Larimar Therapeutics SEC filings (Ticker: LRMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Larimar Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing nomlabofusp for Friedreich’s ataxia and other potential rare-disease programs using an intracellular delivery platform. Its 8-K reports disclose operating and financial results, FDA-related program updates, corporate presentations, material events and risk language around product development, regulatory review, capital needs and clinical execution.
The company’s SEC record also includes capital-structure and governance disclosures. Filings describe registered common stock on the Nasdaq Global Market, equity financing activity, an exchange involving Series A convertible preferred stock, preferred-stock conversion limitations, shareholder voting matters, executive compensation and board governance through proxy materials.
Larimar Therapeutics, Inc. reported results of its 2026 annual stockholder meeting. As of the March 25, 2026 record date, 103,882,937 common shares were outstanding and entitled to vote.
Stockholders elected Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt as Class III directors, approved 2025 executive compensation on an advisory basis, and indicated a preference for holding future say-on-pay votes every year. The Board has decided to follow this annual frequency.
Stockholders ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 and approved an amendment to increase authorized common shares from 115,000,000 to 215,000,000. They also approved a potential adjournment related to the share increase, although it was ultimately not needed.
Blue Owl Capital Holdings LP reported beneficial ownership of 10,739,492 shares of Larimar Therapeutics, Inc. common stock, representing 9.99% of the class. The position includes 7,120,007 shares of common stock, 975,700 shares issuable upon exercise of 9,757 call options, and 2,643,785 shares issuable upon conversion of Series A preferred stock. The reporting statement cites 103,882,937 shares outstanding as of March 17, 2026.
Larimar Therapeutics reported a net loss of $29.6 million for the quarter ended March 31 2026, similar to the prior year’s $29.3 million, as it continues to invest heavily in developing nomlabofusp for Friedreich’s ataxia.
Research and development expenses were $25.0 million and general and administrative costs were $6.1 million. Cash, cash equivalents and marketable securities rose to $200.4 million, helped by a February underwritten equity offering that generated net proceeds of about $107.6 million.
Larimar ended the quarter with an accumulated deficit of $464.4 million but believes its current cash can fund operations for at least twelve months. The FDA granted Breakthrough Therapy Designation to nomlabofusp, and the company plans a rolling BLA starting in June 2026, targeting a potential U.S. launch in the first half of 2027 if approved.
Larimar Therapeutics reported first quarter 2026 results while advancing nomlabofusp toward potential approval for Friedreich’s ataxia. The company held $200.4 million in cash, cash equivalents and marketable securities as of March 31, 2026, supporting a projected cash runway into the second quarter of 2027.
Larimar posted a first quarter 2026 net loss of $29.6 million, or $0.31 per common share, with research and development expenses of $25.0 million and general and administrative expenses of $6.1 million. A February underwritten equity offering raised net proceeds of $107.6 million, strengthening the balance sheet.
Regulatory momentum continued as the FDA granted Breakthrough Therapy Designation for nomlabofusp and reaffirmed willingness to consider skin frataxin levels as a surrogate endpoint. Larimar plans a rolling BLA beginning in June 2026 and expects to submit final modules, including CMC, in the second half of 2026, targeting a potential U.S. launch in the first half of 2027 if approved.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report joint beneficial ownership of 3,625,278 shares of Larimar Therapeutics common stock, representing 3.5% of the class.
The filing is an Amendment No. 2 to a Schedule 13G/A and states the disclosed shares are held by entities subject to voting and investment discretion by the reporting persons. A Joint Filing Agreement dated April 29, 2026 is attached.
Larimar Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on May 19, 2026, including a proposal to amend its charter to increase authorized common stock from 115,000,000 to 215,000,000 shares.
Stockholders will also vote on electing three Class III directors through 2029, advisory approvals of executive compensation and its voting frequency, ratifying PricewaterhouseCoopers as auditor for 2026, and a potential adjournment if there are insufficient votes for the share increase. The proxy highlights recent progress for nomlabofusp in Friedreich’s ataxia, including FDA Breakthrough Therapy Designation, alignment under the START pilot program toward a Biologics License Application using skin FXN as a surrogate endpoint, and positive long‑term open‑label data. It also notes two underwritten equity offerings in 2025–2026 raising roughly $65.0 million and $107.6 million in net proceeds, director and executive pay structures with a high proportion of at‑risk, performance‑based compensation, and a largely independent, six‑member staggered board with separate chair and CEO roles.
Larimar Therapeutics, Inc. is soliciting proxies for its 2026 virtual Annual Meeting on May 19, 2026 to vote on director elections, executive compensation advisory items, ratification of PwC as auditor, and a proposal to increase authorized common stock from 115,000,000 to 215,000,000. The record date for voting was March 25, 2026, when 103,882,937 shares of common stock were outstanding.
The Proxy Statement summarizes Board composition, governance practices, director and executive compensation, recent corporate highlights (including FDA Breakthrough Therapy designation for nomlabofusp and two 2025 underwritten offerings raising net proceeds of approximately $65.0 million and $107.6 million), audit fees and recommended votes. The Board recommends approval of all proposals, including the charter amendment to increase authorized shares.
Larimar Therapeutics is a clinical-stage biotech focused on rare diseases, led by nomlabofusp for Friedreich’s ataxia (FA). Nomlabofusp uses a cell-penetrating peptide platform to deliver frataxin into mitochondria, aiming to correct the underlying protein deficiency in FA rather than just symptoms.
The company has completed four clinical studies and is running an open-label trial with daily 50 mg dosing, where roughly 8,000 doses have been given. Nomlabofusp holds multiple U.S. and European regulatory designations, participates in FDA’s START pilot, and has Breakthrough Therapy status. Larimar targets a June 2026 BLA submission for accelerated approval using skin frataxin as a surrogate endpoint, alongside a global Phase 3 confirmatory study.
Safety is a key focus: injection site reactions are the most common adverse events, and anaphylaxis has been identified as a likely drug-related reaction, leading to protocol changes including premedication and modified initial dosing. As of December 31, 2025, cash, cash equivalents and marketable securities were $136.9 million, and a February 2026 equity offering added $107.6 million in net proceeds, which together are expected to fund operations into the second quarter of 2027.
Larimar Therapeutics reported a full-year 2025 net loss of $165.7 million, or $2.27 per common share, compared with a net loss of $80.6 million, or $1.32 per share, in 2024. Fourth quarter 2025 net loss was $62.5 million, or $0.73 per common share.
Research and development spending nearly doubled to $154.2 million in 2025, mainly from higher nomlabofusp manufacturing, clinical, and regulatory costs. The FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, and the company plans a June 2026 BLA submission with a potential U.S. launch in the first half of 2027, if approved. Cash, cash equivalents and marketable securities were $136.9 million at December 31, 2025, and pro forma liquidity of $244.5 million including the February 2026 offering is expected to fund operations into the second quarter of 2027.